Good morning. It's September 7.

Your DNA contains jumping genes. SIRT1 is the protein keeping them in place - and as NAD+ declines with age, that protection quietly weakens. New research just mapped exactly what happens next.

The rundown:

Let's get to it. 👇

A study of people over 90 found that dementia risk remains strongly shaped by sex, race and genetics - but some stayed cognitively sharp despite carrying major risk factors - understanding what gives those individuals their resilience is increasingly where research is pointing. ScienceDaily

Eight Sleep launched a Biological Age feature in partnership with Bryan Johnson - the $1.5 billion smart-mattress company now turns the biometric data your bed collects every night into an estimate of how fast you're aging. Biological age from your sleep data, automatically, every morning. This is what happens when consumer hardware takes the longevity diagnostic pitch seriously. Eight Sleep

Aging may be partly fueled by immune cells losing their ability to clear away damaged, inflammation-promoting cells - and blocking a single receptor restored that cleanup in mice - reduced chronic inflammation, improved organ and muscle health. Fixing the immune system's cleanup capacity rather than killing senescent cells directly. ScienceDaily

Four Seasons partnered with Lanserhof - one of Europe's most respected medical wellness clinics - to bring a full longevity program aboard its brand-new yachts - guests get advanced diagnostics and health optimization while sailing the Mediterranean. Luxury travel and longevity medicine converging on the same booking. Four Seasons

A bacterial enzyme called LplA, introduced via gene therapy, improved mitochondrial function in mammalian models - a bacterial enzyme that mammalian cells don't produce naturally was able to restore mitochondrial efficiency - an unusual proof of concept for cross-species biological solutions to aging. Fight Aging!

SIRT1 is one of the most talked-about longevity proteins in popular science. NMN and NAD+ supplements exist largely to support it. The field has studied sirtuins for two decades. And yet a study published August 31 identified a SIRT1 role most of the coverage has missed entirely.

SIRT1 is one of the main defenses against jumping genes.

Your genome contains mobile genetic elements called retrotransposons - sometimes called LINE-1 elements or jumping genes. These sequences can transcribe themselves into RNA, copy themselves back into DNA, and insert into a completely new location in the genome. They're parasitic elements making up a significant fraction of the human genome, and for most of your life your cells suppress them. The suppression is the key part. Each insertion disrupts the genome at the insertion site. Over time, accumulating retrotransposon insertions cause genomic instability - one of the Hallmarks of Aging - and trigger inflammatory responses that drive age-related disease.

The science breakdown:

The practical implication: interventions that support SIRT1 - caloric restriction, time-restricted eating, NAD+ precursors, exercise - now have a more specific mechanism to explain their effects. It's not just metabolic efficiency. It's keeping jumping genes in place as the molecular machinery that holds them down weakens with age. That's a more concrete argument than most supplement marketing uses.

👉 Lifespan.io

Every civilization has had to make peace with growing old. Ours may be the first that doesn't. The Long Game is the story of how we got here, what's happening now, and where we are headed.

Producers of the longevity documentary Forever Young spent many hours filming and interviewing the world's top longevity scientists - the founders of the field.

They turned it into The Long Game - a 21-chapter deep dive into the science of longevity, featuring contributions from scientists you don't normally get in the same room: Dr. Eric Verdin, Dr. Nir Barzilai, Dr. Richard Miller, Dr. Steve Horvath and Dr. Thomas Lewis.

This is not a summary course. This is exclusive access to the people doing the scientific breakthrough work. Twenty-one chapters that build the foundation to evaluate longevity science yourself.

👉 Get The Long Game

The standard narrative on Alzheimer's early detection goes roughly like this: amyloid plaques accumulate in the brain, eventually triggering a cascade of damage that leads to cognitive decline. PET scans that detect amyloid are considered our best current tool for catching the disease early.

New research published September 2 suggests that by the time amyloid is visible on those PET scans, the brain may already have been changing for seven years.

Researchers tracked healthy older adults with repeated brain imaging over nearly two decades. Before amyloid became detectable on PET, they found measurable changes in the brain - structural and functional alterations that preceded the appearance of plaques by at least seven years.

The implications run in several directions:

The study doesn't tell us what those pre-amyloid brain changes are, or which ones are most predictive. That's the next layer of research. What it does tell us: the earliest stages of Alzheimer's are happening in brains that look fine on current clinical tests. That's a meaningful gap - and closing it is where most of the early-detection investment in the field is now going.

👉 ScienceDaily

Longevity biotech investment hit USD 3.74 billion in Q1 2026 alone - up 56% year over year, on pace for USD 8-9 billion full year. Those numbers get quoted constantly. What gets quoted less is where the money actually goes - which is not, it turns out, where the narrative says it goes.

A new analysis published September 6 in BioPharma APAC maps longevity capital across four channels. The findings are clarifying.

Therapeutics. Small, and financed through instruments that venture trackers can't see. Pharma collaborations (Gero's USD 250M milestone deal with Chugai), listed company cash flows, grants, public equity. Pure-play longevity venture equity is a minority of the money moving into longevity therapeutics worldwide.

Diagnostics. Empty. The analysis found zero disclosed biological age diagnostics rounds above USD 5 million globally across the first eight months of 2026. Not a few. Zero - confirmed against multiple trackers that specifically lowered their threshold to catch small rounds.

The explanation is the most important line in the piece: investors believe biological age measurement is not yet a business, because there's no regulated market to grow into. No qualified surrogate endpoint, no payer system that can value an aging claim, no moat that a clinic can't replicate by white-labelling the same assay. "The tool that would unlock the category is unfunded precisely because the people with the strongest financial incentive to unlock it have concluded, for now, that it will not unlock on any timeline they can underwrite."

Service operators. Where most of the money actually is - and where no tracker was built to look. Clinics generate their own growth from customers at price points that fund expansion (Singapore's Chi Longevity: SGD 4,250-18,000 per package). Japan's regenerative medicine provision economy runs through 1,000+ active provision plans and 10,000+ patients annually, entirely through self-pay. None of this appears in any funding database.

The parallel channel. Regional science monetized through external vehicles. Orforglipron - the first oral GLP-1 agonist, approved in the US April 2026, likely the world's first mass-market longevity-adjacent drug - was discovered by Chugai, a Japanese company. Every dollar of its revenue accrues to an American company under license. That value appears in no regional column anywhere.

The conclusion: the money is downstream of evidence, arranged precisely around where evidence is and is not required. Heavily into services where none is needed. Selectively into therapeutics through non-aging indications. Not at all into measurement - because measurement's entire value depends on a regulatory future nobody will fund on spec.

The three events that would change the reading: a disclosed biological age diagnostics round above USD 5M, a longevity-dedicated fund above USD 100M deploying into the category, or a clinic raising institutional equity on the strength of published outcome data. None has happened. Until they do, the allocation is the message.

👉 BioPharma APAC (full analysis)

You’ll finally sleep through the night. Pique's Deep Hydration Protocol sells out every fall — get 20% off for life before it's gone.

Shop It Now

Gawande is a Harvard surgeon. This book asks what a good aging life actually looks like - and argues medicine consistently gets it wrong, optimizing for survival metrics at the expense of what patients actually care about. The essential counterweight to every longevity protocol: not how long, but what for.

👉 Get Being Mortal

The future of cancer treatment is coming 👇

Ad slots are filling up fast. To promote your longevity / biohacking product to our niche audience, see the media kit and get in touch with Sebastian at [email protected]